Meghan R Flanagan1, Mara H Rendi2, Kristine E Calhoun1, Benjamin O Anderson1, Sara H Javid3. 1. Department of Surgery, University of Washington Medical Center, Seattle, WA, USA. 2. Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA, USA. 3. Department of Surgery, University of Washington Medical Center, Seattle, WA, USA. sjavid@uw.edu.
Abstract
BACKGROUND: Pleomorphic lobular carcinoma in situ (PLCIS) is an unusual variant of LCIS for which optimal management remains unclear. METHODS: We conducted a 15-year (2000-2014) retrospective chart review of the radiologic, pathologic, clinical management, and recurrence rates of patients with PLCIS on diagnostic biopsy. Fifty-one patients were found to have PLCIS either alone or with concomitant breast cancer. Of these, 23 were found to have pure PLCIS on diagnostic biopsy. Rates of upstaging after local excision, positive or close margins, mastectomy, and recurrence associated with pure pleomorphic lobular carcinoma in situ were examined. RESULTS: Of the 21 patients who underwent surgical excision following diagnostic biopsy, 33.3 % (7/21) were found to have invasive carcinoma, and 19 % (4/23) were found to have ductal carcinoma in situ. Extensive or multifocal PLCIS was present in 47.6 % (10/21) of patients, corresponding to at least one PLCIS-positive or close margin in 71.4 % (15/21). In total, there were 11 local re-excisions in nine patients, and 12 mastectomies. No ipsilateral breast cancer events have occurred, including in those with positive or close surgical margins (mean follow-up 4.1 years). CONCLUSIONS: Patients with isolated PLCIS on diagnostic biopsy are at high risk of upgrading to invasive cancer or ductal carcinoma in situ at diagnostic excision. PLCIS often is extensive, with high rates of positive or close surgical resection margins. If negative PLCIS margins are pursued, rates of successful breast conservation are low. In light of this and low recurrence rates, caution should be exercised in aggressively treating PLCIS with excision to clear margins.
BACKGROUND:Pleomorphic lobular carcinoma in situ (PLCIS) is an unusual variant of LCIS for which optimal management remains unclear. METHODS: We conducted a 15-year (2000-2014) retrospective chart review of the radiologic, pathologic, clinical management, and recurrence rates of patients with PLCIS on diagnostic biopsy. Fifty-one patients were found to have PLCIS either alone or with concomitant breast cancer. Of these, 23 were found to have pure PLCIS on diagnostic biopsy. Rates of upstaging after local excision, positive or close margins, mastectomy, and recurrence associated with pure pleomorphic lobular carcinoma in situ were examined. RESULTS: Of the 21 patients who underwent surgical excision following diagnostic biopsy, 33.3 % (7/21) were found to have invasive carcinoma, and 19 % (4/23) were found to have ductal carcinoma in situ. Extensive or multifocal PLCIS was present in 47.6 % (10/21) of patients, corresponding to at least one PLCIS-positive or close margin in 71.4 % (15/21). In total, there were 11 local re-excisions in nine patients, and 12 mastectomies. No ipsilateral breast cancer events have occurred, including in those with positive or close surgical margins (mean follow-up 4.1 years). CONCLUSIONS:Patients with isolated PLCIS on diagnostic biopsy are at high risk of upgrading to invasive cancer or ductal carcinoma in situ at diagnostic excision. PLCIS often is extensive, with high rates of positive or close surgical resection margins. If negative PLCIS margins are pursued, rates of successful breast conservation are low. In light of this and low recurrence rates, caution should be exercised in aggressively treating PLCIS with excision to clear margins.
Authors: Harold J Burstein; Kornelia Polyak; Julia S Wong; Susan C Lester; Carolyn M Kaelin Journal: N Engl J Med Date: 2004-04-01 Impact factor: 91.245
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Miraj G Shah-Khan; Xochiquetzal J Geiger; Carol Reynolds; James W Jakub; Elizabeth R Deperi; Katrina N Glazebrook Journal: Ann Surg Oncol Date: 2012-07-31 Impact factor: 5.344
Authors: Chandandeep S Nagi; James E O'Donnell; Mikhail Tismenetsky; Ira J Bleiweiss; Shabnam M Jaffer Journal: Cancer Date: 2008-05-15 Impact factor: 6.860
Authors: Marina De Brot; Starr Koslow Mautner; Shirin Muhsen; Victor P Andrade; Anita Mamtani; Melissa Murray; Dilip Giri; Rita A Sakr; Edi Brogi; Tari A King Journal: Breast Cancer Res Treat Date: 2017-06-13 Impact factor: 4.872
Authors: Isabelle L Crary; Elizabeth U Parker; Kathryn P Lowry; Pranav P Patwardhan; Thing Rinda Soong; Sara H Javid; Kristine E Calhoun; Meghan R Flanagan Journal: Ann Surg Oncol Date: 2022-07-08 Impact factor: 4.339
Authors: Faina Nakhlis; Fisher D Katlin; Samantha C Grossmith; Ashley DiPasquale; Beth T Harrison; Stuart J Schnitt; Tari A King Journal: Ann Surg Oncol Date: 2022-06-30 Impact factor: 4.339
Authors: M Gabriela Kuba; Melissa P Murray; Kristen Coffey; Catarina Calle; Monica Morrow; Edi Brogi Journal: Mod Pathol Date: 2021-04-06 Impact factor: 7.842